Dr Christina Yeung

Dr Christina Yeung is a Principal Investigator (PI) at Hammersmith Medicines Research (HMR), part of Nucleus Network, where she leads the delivery of early-phase clinical trials and contributes to the safe and effective execution of complex study protocols. Since joining HMR in 2021, she has progressed through a series of roles including Screening Physician and Clinical Research Physician, before being promoted to Senior Research Physician in 2024. She is also an MHRA-accredited First-in-Human PI. Her progression reflects both her growing leadership responsibilities and her strong contribution to clinical trial delivery across multidisciplinary teams.

In her role, Christina is actively involved in Phase I and II clinical trials, including study oversight, participant safety, and protocol implementation. She brings a strong grounding in human pharmacology, further supported by postgraduate qualifications including a Certificate in Human Pharmacology and a Diploma in Pharmaceutical Medicine. Her continued professional development, including advanced training in psychedelic research and appraisal leadership, underpins her ability to manage both clinical and operational aspects of early-phase research.

Christina has over a decade of prior clinical experience, having worked in family medicine in Hong Kong before entering the clinical research field. This background provides her with a broad clinical perspective that enhances her approach to clinical trials and safe management of subjects. She has also contributed to research outputs in areas such as skin challenge model in early-phase studies, demonstrating her active engagement in advancing clinical research and supporting the development of new therapies.